No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IGXT Intelgenx Technologies Corp.
- 0.167000
- 0.0000000.00%
15min DelayClose Jul 22 09:30 ET
29.17MMarket Cap-2783P/E (TTM)
0.000000High0.000000Low0Volume0.167000Open0.167000Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)174.66MShares0.21000052wk High-1.90P/B10.89MFloat Cap0.09000052wk Low--Dividend TTM65.19MShs Float1.900000Historical High--Div YieldTTM0.00%Amplitude0.090000Historical Low--Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Intelgenx Provides Update on Previously Announced Sale and Investment Solicitation Process
Express News | Intelgenx Obtains Preliminary Efficacy Results for the ‘Buena’ Montelukast Versafilm® Phase 2a Clinical Trial in Patients With Mild to Moderate Alzheimer’s Disease
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the "Company" or "IntelGenx" a subsidiary of IntelGenx Technologies Corp.) (OTCQB:IGXT, TSX:IGX), was granted protection pursuant to an order (as amended or
IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives
IntelGenx (IGX.TO) over the holiday weekend said that it secured an initial order from the Quebec Superior Court (Commercial Division) granting protection to the company and its subsidiaries under the
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of Its Strategic Alternatives
Intelgenx Technologies Corp. | 10-Q: Quarterly report
Comments
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals(CNSP.US$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics(DRMA.US$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals(CNSP.US$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics(DRMA.US$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...
6
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Joy Boy Myth : this guy's good. why never post again...